David Epstein, Seagen CEO
Seagen quietly doles out cell therapy patent rights, but scope remains unclear
On the heels of its $43 billion buyout by Pfizer, Seagen is slimming its cell therapy efforts.
The big biotech signed a licensing deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
